NASDAQ:ONVO Organovo (ONVO) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ONVO Stock Alerts $0.91 -0.04 (-4.23%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.89▼$0.9750-Day Range$0.91▼$1.3552-Week Range$0.85▼$2.05Volume85,047 shsAverage Volume120,168 shsMarket Capitalization$13.02 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends Get Organovo alerts: Email Address Organovo MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.99Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.74) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.63 out of 5 starsMedical Sector866th out of 915 stocksBiological Products, Except Diagnostic Industry148th out of 152 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Organovo.Read more about Organovo's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.02% of the outstanding shares of Organovo have been sold short.Short Interest Ratio / Days to CoverOrganovo has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Organovo has recently decreased by 57.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOrganovo does not currently pay a dividend.Dividend GrowthOrganovo does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONVO. Previous Next 3.3 News and Social Media Coverage News SentimentOrganovo has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Organovo this week, compared to 0 articles on an average week.Search Interest2 people have searched for ONVO on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Organovo to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Organovo insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Organovo is held by insiders.Percentage Held by InstitutionsOnly 8.23% of the stock of Organovo is held by institutions.Read more about Organovo's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Organovo are expected to grow in the coming year, from ($1.74) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Organovo is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Organovo is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrganovo has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Organovo's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840. Click here to see the details because there’s not much time to prepare. About Organovo Stock (NASDAQ:ONVO)Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.Read More ONVO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONVO Stock News HeadlinesJune 13 at 1:27 AM | americanbankingnews.comStockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)June 7, 2024 | americanbankingnews.comOrganovo Holdings, Inc. (NASDAQ:ONVO) to Post FY2025 Earnings of ($1.40) Per Share, Zacks Small Cap ForecastsJune 6, 2024 | americanbankingnews.comOrganovo (NASDAQ:ONVO) Receives New Coverage from Analysts at StockNews.comJune 6, 2024 | americanbankingnews.comZacks Small Cap Weighs in on Organovo Holdings, Inc.'s FY2027 Earnings (NASDAQ:ONVO)May 21, 2024 | globenewswire.comOrganovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel DiseaseMay 14, 2024 | globenewswire.comOrganovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)May 8, 2024 | globenewswire.comOrganovo Holdings, Inc. Announces Pricing of $5.25 Million Public OfferingMay 1, 2024 | finance.yahoo.comONVO Announces Very Positive Phase 2 ResultsApril 15, 2024 | msn.comWhy Organovo Stock Is Up TodayApril 15, 2024 | reuters.comOrganovo's fatty liver disease drug meets main goal in mid-stage studyApril 15, 2024 | globenewswire.comOrganovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to PlaceboFebruary 24, 2024 | benzinga.comOrganovo Holdings Stock (NASDAQ:ONVO) Earnings Dates and Earning CallsFebruary 10, 2024 | finance.yahoo.comOrganovo Holdings Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagFebruary 9, 2024 | morningstar.comOrganovo Holdings Inc ONVOFebruary 9, 2024 | finance.yahoo.comONVO Continues ProgressFebruary 8, 2024 | sfgate.comOrganovo: Fiscal Q3 Earnings SnapshotFebruary 8, 2024 | msn.comOrganovo Holdings Unveils Corporate Presentation OnlineJanuary 25, 2024 | finance.yahoo.comOrganovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis CongressJanuary 9, 2024 | finance.yahoo.comOrganovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis CongressDecember 7, 2023 | finanznachrichten.deOrganovo, Inc.: Organovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsDecember 6, 2023 | finance.yahoo.comOrganovo Provides Timing for Release of FXR314 Phase 2 NASH ResultsNovember 13, 2023 | msn.comOVNO Continues Developing Breakthrough TreatmentsNovember 13, 2023 | finance.yahoo.comCORRECTION – Organovo Highlights FXR314 Combination Therapy Potential and PlanNovember 11, 2023 | finance.yahoo.comOrganovo Holdings Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.38 loss in 2Q 2023)November 8, 2023 | finance.yahoo.comOrganovo Highlights FXR314 Combination Therapy Potential and PlanSee More Headlines Receive ONVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2019Today6/15/2024Next Earnings (Estimated)7/11/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ONVO CUSIPN/A CIK1497253 Webwww.organovo.com Phone(858) 224-1000FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,670,000.00 Net MarginsN/A Pretax Margin-13,457.80% Return on Equity-195.52% Return on Assets-142.62% Debt Debt-to-Equity RatioN/A Current Ratio2.12 Quick Ratio1.96 Sales & Book Value Annual Sales$110,000.00 Price / Sales118.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book2.52Miscellaneous Outstanding Shares14,370,000Free Float13,797,000Market Cap$13.02 million OptionableOptionable Beta0.68 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Keith E. Murphy (Age 52)Executive Chairman Comp: $762.74kMr. Thomas P. Hess CPA (Age 60)MBA, President & CFO Comp: $199.32kMs. Vaidehi Joshi (Age 37)Director of Discovery Biology & Director Comp: $91.8kDr. Curtis M. Tyree Ph.D.Senior Vice President of Strategy & Business DevelopmentKey CompetitorsMicrobot MedicalNASDAQ:MBOTCurisNASDAQ:CRISOKYO PharmaNASDAQ:OKYOAligos TherapeuticsNASDAQ:ALGSAchilles TherapeuticsNASDAQ:ACHLView All CompetitorsInsidersDavid GobelSold 19,607 sharesTotal: $31,763.34 ($1.62/share)View All Insider Transactions ONVO Stock Analysis - Frequently Asked Questions How have ONVO shares performed in 2024? Organovo's stock was trading at $1.11 at the beginning of the year. Since then, ONVO stock has decreased by 18.4% and is now trading at $0.9058. View the best growth stocks for 2024 here. Are investors shorting Organovo? Organovo saw a decline in short interest in May. As of May 31st, there was short interest totaling 147,100 shares, a decline of 57.0% from the May 15th total of 342,300 shares. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is currently 0.1 days. View Organovo's Short Interest. When is Organovo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 11th 2024. View our ONVO earnings forecast. How were Organovo's earnings last quarter? Organovo Holdings, Inc. (NASDAQ:ONVO) posted its quarterly earnings results on Thursday, August, 8th. The medical research company reported ($1.00) EPS for the quarter, meeting the consensus estimate of ($1.00). The medical research company earned $0.67 million during the quarter, compared to analysts' expectations of $0.77 million. When did Organovo's stock split? Shares of Organovo reverse split on Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Taylor Crouch's approval rating as Organovo's CEO? 3 employees have rated Organovo Chief Executive Officer Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among the company's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Organovo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Organovo investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Aerojet Rocketdyne (AJRD), Blackstone (BX), LADENBURG THALM/SH SH (LTS), Advanced Micro Devices (AMD), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX) and OPKO Health (OPK). How do I buy shares of Organovo? Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ONVO) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that...Porter & Company | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Organovo Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Organovo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.